Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 2 countries.
Sebastian BraunInstitut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, 04103 Leipzig, Germany.
Sanja JelačaDepartment of Immunology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Bul. Despota Stefana 142, 11060 Belgrade, Serbia.ORCID 0000-0002-9848-6859
Markus LaubeDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstrasse 400, 01328 Dresden, Germany.ORCID 0000-0003-4916-3794
Sven GeorgeInstitute of Pharmaceutical Chemistry, University of Frankfurt, Max-von-Laue-Straße 9, 60438 Frankfurt, Germany.
Bettina HofmannInstitute of Pharmaceutical Chemistry, University of Frankfurt, Max-von-Laue-Straße 9, 60438 Frankfurt, Germany.
Peter LönneckeInstitut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, 04103 Leipzig, Germany.ORCID 0000-0003-1335-0897
Dieter SteinhilberInstitute of Pharmaceutical Chemistry, University of Frankfurt, Max-von-Laue-Straße 9, 60438 Frankfurt, Germany.
Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstrasse 400, 01328 Dresden, Germany.ORCID 0000-0002-1610-1493
Sanja MijatovićDepartment of Immunology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Bul. Despota Stefana 142, 11060 Belgrade, Serbia.
Danijela Maksimović-IvanićDepartment of Immunology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Bul. Despota Stefana 142, 11060 Belgrade, Serbia.ORCID 0000-0002-8006-5079
Evamarie Hey-HawkinsInstitut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, 04103 Leipzig, Germany.ORCID 0000-0003-4267-0603
Goethe University Frankfurt · DELeipzig University · DEUniversity of Belgrade · RSHelmholtz-Zentrum Dresden-Rossendorf · DE
Funding
Deutsche Forschungsgemeinschaft He 1376/54-1Deutsche Forschungsgemeinschaft PI 304/7Deutsche Forschungsgemeinschaft SFB 1039Deutsche Forschungsgemeinschaft Transregio 314061271-CRC/TRR 205/1-2, B10European Social Fund S.B., E.H.-H.Federal Ministry of Education and Research 031L0258BMinistry of Science, Technological Development, and Innovation of the Republic of Serbia 451-03-47/2023-01/200007
6 · The paper itself
Abstract
Targeting inflammatory mediators and related signaling pathways may offer a rational strategy for the treatment of cancer. The incorporation of metabolically stable, sterically demanding, and hydrophobic carboranes in dual cycloxygenase-2 (COX-2)/5-lipoxygenase (5-LO) inhibitors that are key enzymes in the biosynthesis of eicosanoids is a promising approach. The di-
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis and In Vitro Biological Evaluation of · full record | OpenQuestion